OJR 9188

Drug Profile

OJR 9188

Alternative Names: OJ-R9188

Latest Information Update: 26 Mar 2008

Price : $50

At a glance

  • Originator Nippon Organon
  • Class Guanidines; Skin disorder therapies
  • Mechanism of Action Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Reperfusion injury

Most Recent Events

  • 05 Jun 2002 Preclinical trials in Reperfusion injury in Japan (unspecified route)
  • 05 Jun 2002 Preclinical trials in Atopic dermatitis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top